From the Boston University School of Medicine, Boston, Massachusetts 02118 and § Pecs University, 7624 Pecs, Hungary
Received for publication, October 24, 2002, and in revised form, January 13, 2003
![]() |
ABSTRACT |
---|
![]() ![]() ![]() ![]() ![]() ![]() ![]() |
---|
Store-operated cation (SOC) channels and
capacitative Ca2+ entry (CCE) play very important
role in cellular function, but the mechanism of their activation
remains one of the most intriguing and long lasting mysteries in the
field of Ca2+ signaling. Here, we present the first
evidence that Ca2+-independent phospholipase A2
(iPLA2) is a crucial molecular determinant in activation of
SOC channels and store-operated Ca2+ entry pathway. Using
molecular, imaging, and electrophysiological techniques, we show that
directed molecular or pharmacological impairment of the functional
activity of iPLA2 leads to irreversible inhibition of CCE
mediated by nonselective SOC channels and by Ca2+-release-activated Ca2+ (CRAC) channels.
Transfection of vascular smooth muscle cells (SMC) with antisense, but
not sense, oligonucleotides for iPLA2 impaired thapsigargin
(TG)-induced activation of iPLA2 and TG-induced Ca2+ and Mn2+ influx. Identical inhibition of
TG-induced Ca2+ and Mn2+ influx (but not
Ca2+ release) was observed in SMC, human platelets, and
Jurkat T-lymphocytes when functional activity of iPLA2 was
inhibited by its mechanism-based suicidal substrate, bromoenol lactone
(BEL). Moreover, irreversible inhibition of iPLA2
impaired TG-induced activation of single nonselective SOC channels in
SMC and BAPTA
(1,2-bis(2-aminophenoxy)ethane-N,N,N',N'-tetraacetic acid)-induced activation of whole-cell CRAC current in rat basophilic leukemia cells. Thus, functional iPLA2 is required for
activation of store-operated channels and capacitative Ca2+
influx in wide variety of cell types.
Activation of specific Ca2+-conducting channels in
plasma membrane is triggered by depletion of intracellular
Ca2+ stores in a wide variety of cell types, but the exact
molecular mechanism of such communication remains controversial (1-3). Two types of SOC channels have been described so far, which have distinct biophysical properties, but are activated under the same conditions, by depletion of intracellular Ca2+ stores with
agonists, inhibitors of sarco-endoplasmic reticulum Ca2+-ATPase (SERCA) and/or strong Ca2+
chelators. First, Ca2+ release-activated
Ca2+-selective
(CRAC)1 channels have been
found (4) and extensively described on the level of whole-cell current
in a variety of nonexcitable cells, including Jurkat T-lymphocytes and
RBL cells (Refs. 5-8, and for review, see Ref. 9). Second,
nonselective SOC channels of small, but resolvable 3 pS conductance has
been found and described on single channel and whole-cell current
levels by us (10, 11) and by others (12-18) in vascular SMC and human
platelets. Despite a great physiological importance of both types of
SOC channels, the molecular mechanism of their activation is still unresolved.
In reviewing Ca2+-independent processes that can be
activated by the depletion of intracellular Ca2+ stores in
the presence of strong Ca2+ chelators, the
Ca2+-independent phospholipase A2
(iPLA2) attracted our attention as it is activated under
the same conditions as those known to trigger activation of SOC
channels and CCE. Indeed, it has been recently shown that
iPLA2 can be activated by depletion of Ca2+
stores (19, 20) caused by vasopressin, as well as by thapsigargin (TG,
an inhibitor of SERCA (21)), both in the presence and absence of
intracellular BAPTA (19). In the field of store-operated channels
iPLA2 has not yet been considered as a potentially
important element in signal transduction, but a significant role of
iPLA2 in remodeling of cellular phospholipids (22, 23), and
growing evidence of its involvement in a variety of agonist-triggered signaling cascades (see Ref. 24 for review) suggests that it may be a
multifaceted enzyme, with multiple physiologically important functions
in numerous cell types and tissues.
In this study we sought to determine whether iPLA2 could be
involved in activation of SOC channels and CCE, and we obtained very
intriguing and largely unexpected results. Here we provide the first
experimental evidence that iPLA2 is a crucial molecular determinant in activation of SOC channels and capacitative
Ca2+ influx in a variety of cell types, including SMC,
platelets, Jurkat T-lymphocytes, and RBL cells.
Cells--
Primary culture SMC from mouse (mSMC) and rabbit
(rSMC) aorta were prepared as described previously (10, 25). Human
platelets were prepared from the platelet-rich plasma as described
previously (26). Jurkat T-lymphocytes and RBL cell lines were kept in
culture using standard technique.
Electrophysiology--
Single channel currents were recorded in
mSMC in cell-attached or inside-out configuration using an Axopatch
200B amplifier as described previously (10). Pipettes with tip
resistance of 10-20 M
Whole-cell currents were recorded in RBL cells using standard
whole-cell (dialysis) patch clamp technique. An Axopatch 200B amplifier
was used; data were digitized at 5 kHz and filtered at 1 kHz. Pipettes
were used with tip resistance of 2-4 M Intracellular Ca2+ Measurement--
SMC, platelets,
and Jurkat cells were loaded with fura-2AM, and quantitative changes in
intracellular Ca2+ (fura-2,
F340/F380) were monitored
as described previously (10, 11, 25). For summary data, Mn2+ Influx--
The rate of Mn2+
influx-induced fura-2 quenching was used to estimate divalent cation
influx into SMC, as we described previously (25). The rate of influx
was estimated from the slope during the first 20 s after
Mn2+ (100 µM addition). The summary data are
shown without subtraction of the basal influx that was negligible
(0.09 ± 0.02, n = 15).
Molecular Studies--
Membrane proteins were extracted from
cultured rSMC collected from P100 dish in Tris buffer (50 mM Tris·HCl (pH = 7.5)) with protease inhibitors (1 mM phenylmethylsulphonyl fluoride, 10 µg/ml aprotinin, 10 µg/ml leupeptin, 10 µg/ml pepstatin, and 1 mM EDTA), then sonicated four times for 10 s with 15-s breaks between
cycles, spun down at 500 × g for 10 min at 4 °C,
and the supernatant was collected for further centrifugation at
100,000 × g for 60 min at 4 °C. The pellet was
re-suspended in the Tris buffer (with protease inhibitors). The amount
of protein in membrane fractions was determined, and the samples were
aliquoted (50 µg each), frozen, and stored at
Western blots were done using standard methods: samples were loaded on
a 7.5% SDS-polyacrylamide gel for electrophoresis. Proteins were
transferred to nitrocellulose membranes in transfer buffer (25 mM Tris, 192 mM glycine, 20% methanol) at 40 V
overnight. The membrane was then blocked in PBST (PBS containing 0.05%
Tween 20) with 3% milk for 30 min and then incubated with primary
(anti-iPLA2) antibody in the same buffer for 2 h at
room temperature. After washing, membranes were incubated with
horseradish peroxidase-conjugated secondary antibody (anti-rabbit IgG)
for 1 h in PBST with 3% milk. The signal was detected by enhanced
chemiluminescence (ECL) reagent (Pierce) and exposure to X-Omat films.
Polyclonal antibody directed against a unique domain in the
iPLA2A isoform (Cayman Chemicals) was used to confirm
protein expression in plasma membrane fraction from rSMC and mSMC.
A 20-base-long antisense corresponding to the conserved nucleotides
59-78 in iPLA2A sequence was utilized (ASGVI-18;
5'-fluorescein-CTCCTTCACCCGGAATGGGT-3') (27). As a control, the sense
compliment of ASGVI-18 was used (SGV-18;
5'-fluorescein-ACCCATTCCGGGTGAAGGAG-3'). Both ASGVI-18 and SGVI-18
contained phosphorothioate linkages to limit their degradation and were
labeled with fluorescein, and its presence in the cells was verified by
imaging (excitation at 480 nm, emission at 515 nm) before the
experiments. rSMC were transfected on days 6-7 (60-70% confluence)
using Lipofectamine plus (Invitrogen) and following the standard
protocols. The transfection rate was more than 70% in SMC.
iPLA2 Activity--
The activity of
iPLA2 was determined using the following assay. Briefly,
after specific treatments (as described under "Results") rSMC and RBL cells were collected (using rubber policeman to lift them
up), sonicated, and centrifuged at 20,000 × g for 20 min at 4 °C. The supernatant was removed and kept on ice. The amount of protein was determined, and the assay was performed the same day
using a modified kit originally designed for cPLA2
(cPLA2 assay kit, Cayman Chemicals). To detect the activity
of iPLA2 and not cPLA2, the phospholipase
activity was assayed by incubating the samples with the substrate,
arachidonoyl thio-PC
(1-hexadecyl-2-arachidonylthio-2-deoxy-sn-glycero-3-phosphocholine) for 1 h at 20 °C in a modified Ca2+-free buffer of
the following composition (in mM): 4 EGTA, 160 HEPES (pH
7.4), 300 NaCl, 8 Triton X-100, 60% glycerol, and 2 mg/ml of
BSA. The reaction was stopped by addition of
5,5'-dithiobis(nitrobenzoic acid) for 5 min, and the absorbance
was determined at 405 nm using a standard plate reader. The activity of
iPLA2 was expressed in units = absorbance/mg of protein.
Drugs and Treatments--
BEL (or HELSS) was purchased
from Calbiochem and Sigma. The iPLA2 polyclonal antiserum
was from Cayman Chemicals. The iPLA2A sense and antisense
oligonucleotides were from Sigma. All other drugs were from Sigma.
Please, notice that inhibition of iPLA2 with BEL is
irreversible, requires basal activity of this enzyme, and strongly
depends on temperature, time of treatment, and concentration used. When
applied to the intact cells it also needs time to permeate into the
cell. In most cell types the optimal conditions for BEL treatment (to
ensure complete inhibition of iPLA2) are the following: intact cells need to be pretreated (in bath solution not containing BSA
or serum) with 20-100 µM BEL for 30 min at
37-40 °C, and then BEL can be washed away before the beginning of
the experiments.
Statistical Analysis--
Group data are presented as mean ± S.E. Single or paired Student's t test was used
to determine the statistical significance of the obtained data. The
significance between multiple groups was evaluated using analysis of
variance. The difference was considered significant at
p < 0.05 and is marked by * in the figures.
First, we confirmed that iPLA2 is present and
functionally active in aortic SMC. Fig.
1A shows that
iPLA2A isoform can indeed be detected in both rabbit (rSMC)
and mouse (mSMC) aortic SMC by Western blotting with a specific
polyclonal antibody. Next we tested whether depletion of
Ca2+ stores increases the activity of iPLA2. To
effectively deplete Ca2+ stores, we used a combined BAPTA
and TG treatment. rSMC were first loaded with BAPTA-AM (20 µM for 20 min, which we have previously shown to
effectively buffer intracellular Ca2+ in these cells (28)),
and then TG (5 µM) was applied for 10 min. After this
treatment, we found the activity of iPLA2 to increase 2.6-fold in comparison with basal level in untreated cells (Fig. 1B), which confirmed that depletion of Ca2+
stores causes activation of iPLA2.
INTRODUCTION
TOP
ABSTRACT
INTRODUCTION
MATERIALS AND METHODS
RESULTS
DISCUSSION
REFERENCES
MATERIALS AND METHODS
TOP
ABSTRACT
INTRODUCTION
MATERIALS AND METHODS
RESULTS
DISCUSSION
REFERENCES
were coated with Sylgard. Data were digitized
at 5 kHz and filtered at 1 kHz. Representative single channel current
traces were additionally filtered at 500 Hz for better visual
resolution of small conductance (3 pS) channels. Open channel
probability (NPo) was analyzed and plotted over
time to illustrate the time course of the activity of all 3-pS channels
present in membrane patch. Single channel currents were recorded at
+100 mV applied to the membrane (
100 applied to the pipette), and
upward current deflections represent channel openings in all the
representative traces. The recording time was limited by the lifetime
of the patch, which usually lasted only 5-10 min. Previously we have shown (10) that native 3-pS SOC channels are the same in mSMC and rSMC.
They conduct equally well Na+, Ca2+, and
Mn2+, so in patch clamp studies Na+ was used as
charge carrier, and pipette and bath solutions had the same composition
(in mM): 140 NaCl, 1 MgCl2, 10 TEA, 10 HEPES (pH 7.4). Experiments were done at 20-22 °C.
. After breaking into the
cell, holding potential was 0 mV, and ramp depolarizations (from
100
to +100 mV, 200 ms) were applied every 5 s. The time course of
CRAC current development was analyzed at
80 mV in each cell
(amplitude was expressed in pA/pF). The maximum current density (in
pA/pF) at
80 mV was determined after 10 min of cell dialysis and
summarized for all the cells tested (with S.E. shown in the figures).
Representative I/V relationships are shown during
ramp depolarization after 10 min of cell dialysis. Passive leakage current with zero reversal potential (at the moment of breaking into
the cell) was subtracted (it was usually higher in cells pretreated
with BEL for 30 min and did not change over time). Intracellular
(pipette) solution contained (in mM): 145 cesium glutamate,
3 MgCl2, 10 BAPTA, 5 TEA, 10 HEPES (pH 7.2). Extracellular solution was (in mM): 20 CaCl2, 1 MgCl2, 130 NaCl, 3 CsCl, 5 HEPES (pH 7.4). In some
experiments BEL (20 µM) was added to the pipette solution. Experiments were done at 20-22 °C.
ratio was
calculated as the difference between the peak ratio after extracellular
Ca2+ was added, and its level right before Ca2+
addition. The summary data are shown without subtraction of the basal
Ca2+ influx that was negligible (0.20 ± 0.01, n = 115). Dual-excitation fluorescence imaging system
(IonOptics) was used for studies of individual SMC, while standard
spectrofluorimeter (Hitachi F-4500) was used for the recording of total
fluorescence from either confluent SMC on coverslips or platelets and
Jurkat cells in suspension. Data were summarized either from the large
number of individual SMC cells (tested in at least three different
experiments/preparations) or from at least five different experiments
when total fluorescence from confluent cells or cells in suspension was recorded.
80 °C until later use.
RESULTS
TOP
ABSTRACT
INTRODUCTION
MATERIALS AND METHODS
RESULTS
DISCUSSION
REFERENCES
View larger version (26K):
[in a new window]
Fig. 1.
The regulation of iPLA2
expression and activity in vascular SMC: effects of Ca2+
store depletion and antisense transfection. A, Western
blot showing the presence of iPLA2 (~82 kDa) protein in
plasma membrane fraction of rSMC and mSMC. B and
C, the activity of iPLA2 (in absorbance/mg of
protein units) in SMC (B) and RBL cells (C) under
basal conditions (basal) and after intracellular
Ca2+ stores were depleted with TG (5 µM for
10 min) in control cells (TG) and in cells pretreated with BEL (25 µM for 30 min at 37 °C) before TG was applied
(BEL+TG). Before the beginning of the experiments, all the
cells were loaded with BAPTA-AM (20 µM for 20 min) to
buffer intracellular Ca2+. D, Western blot and
corresponding densitometry analysis of the amount of iPLA2
protein in plasma membrane fraction of control rSMC and 36 h after
their transfection with specific sense or antisense oligonucleotides
for iPLA2 (A isoform). E, the activity of
iPLA2 (in absorbance/mg of protein units) in SMC
transfected with sense or antisense oligonucleotides (36 h after
transfection) under basal conditions (basal) and after
intracellular Ca2+ stores were depleted with TG (5 µM for 10 min). Before the beginning of the experiments,
all the cells were loaded with BAPTA-AM (20 µM for 20 min) to buffer intracellular Ca2+.
To test the potential role of iPLA2 in activation of
store-operated channels and CCE pathway in SMC, two independent
approaches (molecular and pharmacological) were used. First, rSMC were
transfected with antisense or sense oligonucleotides (labeled with
fluorescin) that were specifically designed for the iPLA2A
isoforms (27). As expected, antisense decreased the level of the
iPLA2A protein expression, which we measured 36 h
after transfection (Fig. 1D). Importantly, transfection of
rSMC with antisense prevented activation of iPLA2 by
depletion of Ca2+ stores; TG/BAPTA treatment caused a
significant increase in iPLA2 activity in rSMC transfected
with sense, but not antisense oligonucleotides (Fig. 1E). At
the same time, transfection of rSMC with antisense, but not sense,
oligonucleotides for iPLA2A significantly reduced TG-induced Ca2+ influx (Fig.
2, A and B).
TG-induced Mn2+ influx (Fig. 2, C and
D), which is considered a more direct measure of ion
channel-mediated cation influx in intact cells, was also inhibited in
rSMC treated with antisense, but not sense, oligonucleotides. These
results for the first time demonstrated that activation of CCE in SMC
is dependent on the functional expression of
iPLA2.
|
To obtain additional and independent evidence that can confirm the
central role of iPLA2 in activation of CCE, we tested
whether mechanism-based inhibition of iPLA2 enzymatic
activity could mimic the effects of iPLA2 antisense
transfection. BEL, a suicidal substrate for iPLA2, is
widely used as an irreversible mechanism-based (time- and
temperature-dependent) inhibitor with a specificity
~1,000 times higher for iPLA2 over other PLA2
isoforms (24, 29). When applied to the intact cells for 30 min at
37-40 °C, 20-100 µM BEL is known to completely
inhibit iPLA2 activity (EC50 = 7 µM) (22), and it is considered to be the most specific
inhibitor of iPLA2-dependent processes in a
variety of cell types. In SMC, we confirmed that pretreatment with BEL
(25 µM for 30 min at 37 °C followed by 20 min washing
prior to the experiments) prevented activation of iPLA2 by
depletion of Ca2+ stores (Fig. 1B) and used BEL
as an additional tool to study the role of iPLA2 in
activation of CCE. Fig. 3 shows the
examples of TG-induced 2-aminoethoxydiphenyl borate (2-APB)-sensitive
Ca2+ (Fig. 3A) and Mn2+ (Fig.
3C) influx in single rSMC. Pretreatment of rSMC with BEL (25 µM for 15-30 min at 37 °C followed by a
10-30-min wash) significantly inhibited both, TG-induced
Ca2+ (Fig. 3, A and B) and
Mn2+ influx (Fig. 2, C and D), which
was identical to the effects of rSMC transfection with
iPLA2 antisense (Fig. 2, A-D). Thus, inhibition
of iPLA2 with BEL mimicked the effects of SMC transfection with specific antisense to iPLA2. Identical effects of the
molecular and pharmacological inhibition of iPLA2 on CCE
not only established the crucial role of iPLA2 in this
process, but also confirmed the use of BEL as a tool for functional
inhibition of iPLA2 in our further studies of
iPLA2-dependent activation of SOC channels.
|
The effect of BEL on capacitative Ca2+ influx was
dose-dependent. Fig.
4A shows that pretreatment of
rSMC with 10-25 µM BEL (for 30 min at 37 °C) produced
significant inhibition of TG-induced Ca2+ influx. The same
inhibitory effect was also observed in mSMC in which BEL (25 µM) reduced TG-induced Ca2+ influx from
r = 2.0 ± 0.2 (n = 20) in
control cells to 0.3 ± 0.1 (n = 15). It is
important that the effect of BEL was irreversible and specific to
Ca2+ influx. BEL did not affect TG-induced Ca2+
release from the stores (Fig. 4A), as indicated by similar
increases in intracellular Ca2+ (recorded in the absence of
extracellular Ca2+) in control and BEL-treated cells.
Similarly, BEL-induced inhibition of TG-induced Ca2+
influx, but not Ca2+ release, was also observed in human
platelets (Fig. 4B), which are known to have store-operated
cation influx that is similar to SMC (11, 26, 30, 31). To eliminate the
potential role of magnesium-dependent phosphatidate
phosphohydrolase (PAP-1) (32) in the effect of BEL on CCE, propranolol
(50-100 µM for 30 min, which is widely used to inhibit
PAP-1 (33), but not iPLA2) was tested. Propranolol did not
inhibit TG-induced Ca2+ influx in both SMC (Fig.
4A) and human platelets (Fig. 4B), which confirmed that BEL-induced inhibition of CCE is mediated by
iPLA2 and not PAP-1.
|
To confirm that the BEL-induced inhibition of Ca2+ and Mn2+ influx indeed resulted from inability of SOC channels to get activated by TG, single SOC channels were recorded in cell-attached membrane patches. Fig. 4C shows that treatment of control SMC with TG (1 µM for 10-20 min) resulted in activation of specific 3-pS nonselective cation SOC channels (described previously in detail (10)), which could be recorded in cell-attached membrane patches (in six out of seven experiments). Consistent with Ca2+ and Mn2+ influx studies, TG failed to activate single SOC channels (Fig. 4D) in SMC in which iPLA2 was inhibited with BEL (five out of five experiments). Rare (1-2/min) openings of 3-pS channels (similar to what is observed in normal resting SMC (10)) could still be detected in cell-attached membrane patches from BEL-pretreated SMC (Fig. 4D), suggesting that BEL does not affect the presence of SOC channels, but inhibits their TG-induced activation. Control experiments showed that BEL pretreatment did not affect the activity of voltage-gated Ca2+ channels and Ca2+-dependent K+ channels in SMC (data not shown), indicating specificity of BEL-induced inhibition of iPLA2 on activation of SOC channels.
To determine whether the role of iPLA2 in CCE is specific
for vascular SMC in which capacitative Ca2+ influx is known
to be mediated by nonselective cation channels (10, 12-18), or may be
a general phenomenon, we also tested the effects of iPLA2
inhibition by BEL in Jurkat T-lymphocytes and in RBL cells. In these
cells CCE is known to be mediated by highly Ca2+-selective
CRAC channels (5-8), which have biophysical properties (9) distinct
from nonselective SOC channels in SMC, but may be guided by the same
store-dependent mechanism. Fig.
5, A and B, show
that in Jurkat cells inhibition of iPLA2 with BEL impaired TG-induced Ca2+ influx, but did not affect Ca2+
release, which was identical to SMC and human platelets (Fig. 4,
A and B).
|
To further confirm that iPLA2 is involved in
store-dependent activation of CRAC channels, we tested the
effect of BEL-induced inhibition of iPLA2 on the whole-cell
CRAC current that develops during cell dialysis with BAPTA in RBL
cells. Similar to SMC, pretreatment of intact RBL cells with BEL (25 µM for 30 min at 37 °C) prevented activation of
iPLA2 upon depletion of Ca2+ stores with TG
(Fig. 1C). Fig. 6,
A and B, show the time courses of the development
of CRAC current (at 80 mV) and corresponding I/V relationships in representative control RBL
cells and in cells pretreated with BEL (30 µM for 30 min
at 37 °C). In all nine control cells tested, a typical CRAC current
developed reaching
2.00 ± 0.15 pA/pF (n = 9)
after 10 min of cell dialysis with BAPTA. Contrary to control, in seven
out of nine cells pretreated with BEL, activation of CRAC channels was
dramatically impaired, and CRAC current was hardly distinguishable
(
0.32 ± 0.14 pA/pF, n = 7). We also tested the
effects of acute intracellular application of BEL on the whole-cell
CRAC current during cell dialysis (by including BEL into the patch
pipette). In these experiments we could not expect to achieve complete
inhibition of iPLA2 in all the cells tested. Indeed, BEL is
known to be a mechanism-based inhibitor that is effective at
physiological temperature (37-40 °C) when iPLA2 is
normally functional. At room temperature (20-22 °C, when enzymatic
activity of iPLA2 is significantly slow), higher concentrations and longer treatment could be required for the mechanism
based suicidal substrates to effectively inhibit the enzyme activity.
Thus, during patch clamp experiments, when BEL was included in the
patch pipette and applied inside the cell during its dialysis, we could
not expect reliable inhibition of iPLA2 in all the cells
during a short 10-15-min recording of CRAC current at room temperature
(20-22 °C), which were the time and temperature limitations in our
patch clamp experiments. Under such nonoptimal condition (low
temperature and short time) one could expect that the effect of BEL may
vary from cell to cell, ranging from full inhibition of CRAC current to
no effect. The results of the experiments (Fig. 6, C and
D) confirmed these expectations. After 10 min of cell
dialysis with BAPTA-containing solution, CRAC current (at
80 mV)
developed in all 14 control cells tested, and on average its density
was
2.4 ± 0.3 pA/pF (n = 14). When BEL (20 µM) was present in the pipette, the total of 12 cells tested could be divided into three groups: (a) in four cells
BEL completely prevented the development of CRAC current, and after 10 min of cell dialysis the inward current was negligible (
0.2 ± 0.1 pA/pF), (b) in four cells CRAC current developed, but
was significantly smaller than control (
1.1 ± 0.3 pA/pF), and
(c) in four other cells maximum CRAC current density was
about the same (or even higher) as in control (
2.8 ± 0.6 pA/pF). Fig. 6, C and D, show and compare the
time course of development and I/V relationships
of the CRAC current in control cells and in three (a-c)
groups of RBL cells acutely treated with BEL. These results confirmed
that functional iPLA2 is indeed required for activation of
CRAC channels in RBL cells.
|
Thus, inhibition of expression or functional activity of
iPLA2 leads to the impairment of
store-dependent activation of SOC channels and capacitative
Ca2+ influx in a variety of cell types.
![]() |
DISCUSSION |
---|
![]() ![]() ![]() ![]() ![]() ![]() ![]() |
---|
These studies demonstrate that iPLA2 is a crucial molecular determinant in activation of store-operated channels and capacitative Ca2+ influx in different cell types. This result is somewhat unexpected, because iPLA2 has never before been considered as an important component of store-operated Ca2+ influx pathway in any of the models proposed so far (see Refs. 34 and 35 for recent review of the existing models).
Our results provide strong evidence that activation of capacitative Ca2+ influx mediated by two types of SOC channels (CRAC in RBL cells and Jurkat T-lymphocytes and nonselective SOC in SMC and platelets) require the presence and functional activity of iPLA2. Molecular (antisense) and functional (BEL) inhibition of iPLA2 produced identical results: in both cases, TG-induced Ca2+ and Mn2+ influx was dramatically and irreversibly impaired, while Ca2+ release from the stores was not affected. Functional inhibition of iPLA2 with BEL also prevented activation of single 3-pS SOC channels and whole-cell CRAC currents upon TG and/or BAPTA-induced depletion of intracellular stores, which provided a convenient pharmacological tool for future studies of the mechanism of iPLA2 involvement in CCE.
Although independent lines of evidence presented here show the crucial role of iPLA2 in the activation of SOC channels and capacitative Ca2+ influx, the exact location of iPLA2 in this pathway, and the molecular mechanism of iPLA2-dependent signal transduction, remain to be determined. It is not clear whether iPLA2 is involved in originating the signal from endoplasmic reticulum upon depletion of Ca2+ stores or if it is localized in the plasma membrane and is involved in accepting the signal and/or mediating signal transduction to the SOC channels. In view of the fact that iPLA2 was detected in plasma membrane fraction of SMC (Fig. 1, A and C), it can be speculated that it may be co-localized with SOC channels in plasma membrane. Our recent studies showed activation of single SOC channels in excised membrane patches by the calcium influx factor (CIF) (36) produced upon depletion of Ca2+ stores, and we would like to speculate that iPLA2 may be directly involved in membrane-delimited activation of SOC channels by CIF. Single SOC channels in excised membrane patches from SMC (10) could be an excellent experimental model to address this possibility.
Arachidonic acid, a main product of all types of PLA2, including iPLA2, does not seem to be involved in direct activation of SOC channels and CCE (37, 38). It is now well established that arachidonic acid has its own specific target, so called ARC channel (39), which may be responsible for a part of agonist-induced Ca2+ influx in some cells. Contrary to SOC channels it is not regulated by intracellular Ca2+ stores and has biophysical, pharmacological, and functional properties that are significantly different from CRAC and nonselective SOC channels (38, 40). Alternatively, the products of arachidonic acid degradation may play some role in the store-operated pathway. Recently, it has been shown that inhibition of the lipo-oxygenase (but not cyclo-oxygenase) family of enzymes reduces CRAC current in RBL cells (41), but the exact mechanism of such effect is not clear. Little is presently known of the potential role of other products of iPLA2. Thus, it remains unclear which products of iPLA2 could be involved in regulation of CCE and SOC channels.
The importance of iPLA2 in cellular function is not limited
to its housekeeping role in phospholipid remodeling (maintenance of
membrane integrity) that involves generation of lysophospholipid acceptors for incorporation of arachidonic acid into phospholipids. Other important signaling functions of iPLA2 have also been
suggested (see Refs. 24 and 42 for the most recent review), including its role in agonist-induced stimulation of smooth muscle (43) and
endothelial cells (44, 45), in lymphocyte proliferation (46), and in
endothelium-dependent vascular relaxation (44). We believe
that introduction of iPLA2 as a novel determinant in the
store-operated Ca2+ influx pathway may open many new
directions for studying physiological and pathological functions in
excitable and nonexcitable cells. It may also shed some new light on
the still mysterious mechanism of activation of store-operated channels.
![]() |
ACKNOWLEDGEMENTS |
---|
We thank Drs. Igor Medina, Diomedes Logothetis, Craig Montell, and Michael Kirber for discussions and Dr. Richard Cohen for continued support and valuable help with the manuscript. We also thank Dr. Indu Ambudkar for providing us with RBL cell line.
![]() |
FOOTNOTES |
---|
* This work was supported by National Institutes of Health Grant HL54150, by American Heart Association Grant 0225688T (to T. S.), and by OTKA Grant F038149 (to P. C.).The costs of publication of this article were defrayed in part by the payment of page charges. The article must therefore be hereby marked "advertisement" in accordance with 18 U.S.C. Section 1734 solely to indicate this fact.
These authors contributed equally to the work.
¶ To whom correspondence should be addressed: Vascular Biology Unit, EBRC, X-704, 650 Albany St., Boston, MA 02118. Tel.: 617-638-7118; Fax: 617-638-7113; E-mail: vbolotina@medicine.bu.edu.
Published, JBC Papers in Press, January 23, 2003, DOI 10.1074/jbc.M210878200
![]() |
ABBREVIATIONS |
---|
The abbreviations used are: CRAC, Ca2+-release-activated Ca2+; RBL, rat basophilic leukemia; SMC, smooth muscle cells; SOC, store-operated cation; iPLA2, Ca2+-independent phospholipase A2; TG, thapsigargin; TEA, tetraethylammonium; BEL, bromoenol lactone; BAPTA-AM, 1,2-bis(2-aminophenoxy)ethane-N,N,N',N'-tetraacetic acid tetrakis(acetoxymethyl ester); PBS, phosphate-buffered saline; 2-APB, 2-aminoethoxydiphenyl borate; PAP, phosphatidate phosphohydrolase; CCE, capacitative Ca2+ entry.
![]() |
REFERENCES |
---|
![]() ![]() ![]() ![]() ![]() ![]() ![]() |
---|
1. | Putney, J. W., Jr., Bird, G., and St, J. (1993) Cell 75, 199-201[Medline] [Order article via Infotrieve] |
2. | Berridge, M. J. (1995) Biochem. J. 312, 1-11[Medline] [Order article via Infotrieve] |
3. | Clapham, D. E. (1995) Cell 80, 259-268[Medline] [Order article via Infotrieve] |
4. | Hoth, M., and Penner, R. (1992) Nature 355, 353-356[CrossRef][Medline] [Order article via Infotrieve] |
5. | Zweifach, A., and Lewis, R. S. (1993) Proc. Natl. Acad. Sci. U. S. A. 90, 6295-6299[Abstract] |
6. | Lewis, R. S. (2001) Annu. Rev. Immunol. 19, 497-521[CrossRef][Medline] [Order article via Infotrieve] |
7. | Parekh, A. B., and Penner, R. (1995) J. Physiol. (Lond.) 489, 377-382[Abstract] |
8. | Fierro, L., Lund, P. E., and Parekh, A. B. (2000) Pfluegers Arch. 440, 580-587[CrossRef][Medline] [Order article via Infotrieve] |
9. |
Parekh, A. B.,
and Penner, R.
(1997)
Physiol. Rev.
77,
901-930 |
10. |
Trepakova, E. S.,
Gericke, M.,
Hirakawa, Y.,
Weisbrod, R. M.,
Cohen, R. A.,
and Bolotina, V. M.
(2001)
J. Biol. Chem.
276,
7782-7790 |
11. | Trepakova, E. S., and Bolotina, V. M. (2002) Membr. Cell Biol. 19, 49-56 |
12. |
Albert, A. P.,
and Large, W. A.
(2002)
J. Physiol. (Lond.)
538,
717-728 |
13. | Wayman, C. P., McFadzean, I., Gibson, A., and Tucker, J. F. (1996) Br. J. Pharmacol. 117, 566-572[Abstract] |
14. | Iwamuro, Y., Miwa, S., Minowa, T., Enoki, T., Zhang, H., Ishikawa, T., Hashimoto, N., and Masaki, T. (1998) Br. J. Pharmacol. 124, 1541-1549[Abstract] |
15. | Golovina, V. A., Platoshyn, O., Bailey, C. L., Wang, J., Limsuwan, A., Sweeney, M., Rubin, L. J., and Yuan, J. X. J. (2001) Am. J. Physiol. 280, H746-H755 |
16. |
Ng, L. C.,
and Gurney, A. M.
(2001)
Circ. Res.
89,
923-929 |
17. | Gibson, A., McFadzean, I., Wallace, P., and Wayman, C. P. (1998) Trends Pharmacol. Sci. 19, 266-269[CrossRef][Medline] [Order article via Infotrieve] |
18. |
McFadzean, I.,
and Gibson, A.
(2002)
Br. J. Pharmacol.
135,
1-13 |
19. |
Wolf, M. J.,
Wang, J.,
Turk, J.,
and Gross, R. W.
(1997)
J. Biol. Chem.
272,
1522-1526 |
20. |
Nowatzke, W.,
Ramanadham, S.,
Ma, Z.,
Hsu, F. F.,
Bohrer, A.,
and Turk, J.
(1998)
Endocrinology
139,
4073-4085 |
21. | Thastrup, O., Cullen, P. J., Drobak, B. K., Hanley, M. R., and Dawson, A. P. (1990) Proc. Natl. Acad. Sci. U. S. A. 87, 2466-2470[Abstract] |
22. | Balsinde, J., Bianco, I. D., Ackermann, E. J., Conde-Frieboes, K., and Dennis, E. A. (1995) Proc. Natl. Acad. Sci. U. S. A. 92, 8527-8531[Abstract] |
23. |
Balsinde, J.,
and Dennis, E. A.
(1997)
J. Biol. Chem.
272,
16069-16072 |
24. | Winstead, M. V., Balsinde, J., and Dennis, E. A. (2000) Biochim. Biophys. Acta 1488, 28-39[Medline] [Order article via Infotrieve] |
25. |
Cohen, R. A.,
Weisbrod, R. M.,
Gericke, M.,
Yaghoubi, M.,
Bierl, C.,
and Bolotina, V. M.
(1999)
Circ. Res.
84,
210-219 |
26. |
Trepakova, E. S.,
Cohen, R. A.,
and Bolotina, V. M.
(1999)
Circ. Res.
84,
201-209 |
27. |
Balsinde, J.,
Balboa, M. A.,
and Dennis, E. A.
(1997)
J. Biol. Chem.
272,
29317-29321 |
28. |
Hirakawa, Y.,
Gericke, M.,
Cohen, R. A.,
and Bolotina, V. M.
(1999)
Am. J. Physiol.
277,
H1732-H1744 |
29. |
Ackermann, E. J.,
Conde-Frieboes, K.,
and Dennis, E. A.
(1995)
J. Biol. Chem.
270,
445-450 |
30. | Sargeant, P., and Sage, S. O. (1994) Pharmacol. Ther. 64, 395-443[CrossRef][Medline] [Order article via Infotrieve] |
31. | Diver, J. M., Sage, S. O., and Rosado, J. A. (2001) Cell Calcium 30, 323-329[CrossRef][Medline] [Order article via Infotrieve] |
32. |
Balsinde, J.,
and Dennis, E. A.
(1996)
J. Biol. Chem.
271,
31937-31941 |
33. |
Balboa, M. A.,
Balsinde, J.,
and Dennis, E. A.
(1998)
J. Biol. Chem.
273,
7684-7690 |
34. |
Putney, J. W.,
Broad, L. M.,
Braun, F.,
Lievremont, J.,
and Bird, G.
(2002)
J. Cell Sci.
114,
2223-2229 |
35. | Venkatachalam, K., van Rossum, D. B., Patterson, R. L., Ma, H.-T., and Gill, D. L. (2002) Nat. Cell Biol. 4, E263-E272[CrossRef][Medline] [Order article via Infotrieve] |
36. |
Trepakova, E. S.,
Csutora, P.,
Marchase, R. B.,
Cohen, R. A.,
and Bolotina, V. M.
(2000)
J. Biol. Chem.
275,
26158-26163 |
37. |
Shuttleworth, T. J.,
and Thompson, J. L.
(1999)
J. Biol. Chem.
274,
31174-31178 |
38. |
Mignen, O.,
Thompson, J. L.,
and Shuttleworth, T. J.
(2001)
J. Biol. Chem.
276,
35676-35683 |
39. |
Mignen, O.,
and Shuttleworth, T. J.
(2000)
J. Biol. Chem.
275,
9114-9119 |
40. |
Mignen, O.,
and Shuttleworth, T. J.
(2001)
J. Biol. Chem.
276,
21365-21374 |
41. |
Glitsch, M. D.,
Bakowski, D.,
and Parekh, A. B.
(2002)
J. Physiol. (Lond.)
539,
93-106 |
42. | Six, D. A., and Dennis, E. A. (2000) Biochim. Biophys. Acta 1488, 1-19[Medline] [Order article via Infotrieve] |
43. |
Jenkins, C. M.,
Han, X.,
Mancuso, D. J.,
and Gross, R. W.
(2002)
J. Biol. Chem.
277,
32807-32814 |
44. |
Seegers, H. C.,
Gross, R. W.,
and Boyle, W. A.
(2002)
J. Pharmacol. Exp. Ther.
302,
918-923 |
45. |
Creer, M. H.,
and McHowat, J.
(1998)
Am. J. Physiol.
275,
C1498-C1507 |
46. |
Roshak, A. K.,
Capper, E. A.,
Stevenson, C.,
Eichman, C.,
and Marshall, L. A.
(2000)
J. Biol. Chem.
275,
35692-35698 |